A French Real-life Study: EvaluatioN of durvALumab utilization and effectiveness for first line extensive stage small cell lung cancer. - ARSENAL

Study identifier:D419QR00014

ClinicalTrials.gov identifier:NCT05683977

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

EvaluatioN of durvALumab utilization and effectiveness for first line extensive stage small cell lung cancer. Prospective Cohort of Extensive Stage Small Cell Lung Cancer Patients treated with durvalumab associated with platinum-etoposide chemotherapy

Medical condition

Small Cell Lung Carcinoma

Phase

N/A

Healthy volunteers

No

Study drug

durvalumab

Sex

All

Actual Enrollment

254

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 14 Nov 2022
Estimated Primary Completion Date: 01 Mar 2027
Estimated Study Completion Date: 01 Mar 2027

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Kappa Santé

Inclusion and exclusion criteria